Marker Therapeutics, Inc.

Equities

MRKR

US57055L2060

Market Closed - Nasdaq Other stock markets 20:00:00 13/03/2026 GMT			5-day change	1st Jan Change
1.330 ^USD	-1.48%		-3.62%	-10.74%

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI

Transcript : Marker Therapeutics, Inc. - Special Call

Published on 08/26/2025 at 05:06 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and welcome to Marker Therapeutics webcast to discuss the Phase I clinical update from the APOLLO study, MT-601 in relapsed lymphoma.

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Marker Therapeutics, Inc.

11-14	Marker Therapeutics Q3 net loss narrows to $2 mln	RE
11-13	Marker Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-05	Marker Therapeutics, Inc. Appoints Kathryn Penkus Corzo to Board of Directors, Effective November 1, 2025	CI
11-05	Marker Therapeutics appoints Kathryn Penkus Corzo to board of directors	RE
11-03	Marker Therapeutics, Inc. Announces Data from Phase 1 APOLLO Study to Present in Two Posters at 67Th American Society of Hematology Annual Meeting and Exposition	CI
06/10/25	Marker Therapeutics, Inc. Announces First Patient Treated in Off-The-Shelf Program	CI
26/08/25	Marker Therapeutics, Inc. - Special Call
26/08/25	Marker Therapeutics Says MT-401 Shows 66% Response Rate in Relapsed Lymphoma Study	MT
14/08/25	Marker Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
29/05/25	Marker Therapeutics, Inc. - Special Call
20/05/25	Marker Therapeutics Reports That Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	CI
20/05/25	Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma	RE
15/05/25	Marker Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
31/03/25	Marker Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
30/03/25	Marker Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI